\ Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label
Company News: Page (1) of 1 - 07/14/17

Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label

Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent and Increased Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed or Refractor...

July 14, 2017 --
This article is no longer available,but here are some related topics.

Page: 1
Related Keywords:Manufacturing,Sales,Applications,Suppliers,Manufacturing/Production,Marketing,Insurance,Shipping & Receiving,Manufacturing,Sales & Marketing,Security,Business Issues,Administration,Legal,Management,Human Resources,Sales,Human Resources,Sales,USA,Korea,IT (Information Technology),Security,Medicine,Disease,

Source:PR Newswire. All Rights Reserved

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved

Webmaster
Privacy.